Abstract |
TP53 is the most frequently altered gene in head and neck squamous cell carcinoma ( HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.
|
Authors | Abdullah A Osman, David M Neskey, Panagiotis Katsonis, Ameeta A Patel, Alexandra M Ward, Teng-Kuei Hsu, Stephanie C Hicks, Thomas O McDonald, Thomas J Ow, Marcus Ortega Alves, Curtis R Pickering, Heath D Skinner, Mei Zhao, Eric M Sturgis, Merrill S Kies, Adel El-Naggar, Federica Perrone, Lisa Licitra, Paolo Bossi, Marek Kimmel, Mitchell J Frederick, Olivier Lichtarge, Jeffrey N Myers |
Journal | Cancer research
(Cancer Res)
Vol. 75
Issue 7
Pg. 1205-15
(Apr 01 2015)
ISSN: 1538-7445 [Electronic] United States |
PMID | 25691460
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | ©2015 American Association for Cancer Research. |
Chemical References |
- Antineoplastic Agents
- TP53 protein, human
- Tumor Suppressor Protein p53
- Cisplatin
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Carcinoma, Squamous Cell
(drug therapy, genetics)
- Cell Line, Tumor
- Cisplatin
(pharmacology)
- Drug Resistance, Neoplasm
- Female
- Gene Expression
- Humans
- Male
- Mice, Nude
- Middle Aged
- Mutation
- Tongue Neoplasms
(drug therapy, genetics)
- Tumor Suppressor Protein p53
(genetics)
- Xenograft Model Antitumor Assays
|